XAIR Stock Overview
A commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Beyond Air, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.52 |
| 52 Week High | US$2.36 |
| 52 Week Low | US$0.30 |
| Beta | -0.18 |
| 11 Month Change | 46.13% |
| 3 Month Change | 23.87% |
| 1 Year Change | -68.96% |
| 33 Year Change | -96.22% |
| 5 Year Change | -89.47% |
| Change since IPO | -91.61% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Beyond Air's (NASDAQ:XAIR) Cash Burn Rate
Apr 05
Will Beyond Air (NASDAQ:XAIR) Spend Its Cash Wisely?
Dec 14Beyond Air presents pilot at-home study data; stock earlier snaps 7-day losing streak
Oct 17Beyond Air: Bottom Line Fundamentals Keep Buyers At Bay
Sep 08Beyond Air affiliate Beyond Cancer doses patient in phase 1 study of ultra-high concentration nitric oxide therapy
Aug 23Beyond Air reaches six-month high after $2.3M insider transactions
Jul 06Shareholder Returns
| XAIR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 8.6% | -0.8% | -1.2% |
| 1Y | -69.0% | 20.9% | 30.4% |
Return vs Industry: XAIR underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: XAIR underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| XAIR volatility | |
|---|---|
| XAIR Average Weekly Movement | 15.5% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XAIR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XAIR's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 107 | Steve Lisi | www.beyondair.net |
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn.
Beyond Air, Inc. Fundamentals Summary
| XAIR fundamental statistics | |
|---|---|
| Market cap | US$37.87m |
| Earnings (TTM) | -US$55.49m |
| Revenue (TTM) | US$2.34m |
16.2x
P/S Ratio-0.7x
P/E RatioIs XAIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XAIR income statement (TTM) | |
|---|---|
| Revenue | US$2.34m |
| Cost of Revenue | US$4.63m |
| Gross Profit | -US$2.29m |
| Other Expenses | US$53.20m |
| Earnings | -US$55.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.77 |
| Gross Margin | -97.61% |
| Net Profit Margin | -2,369.17% |
| Debt/Equity Ratio | 53.3% |
How did XAIR perform over the long term?
See historical performance and comparison